Mondias Naturals Announces the Appointment of Dr. Patrick Frankham as Chief Executive Officer
Momentum Public Relations
Press Release: August 20, 2019
Mondias Natural Products Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce that the Board of Directors has appointed Dr. Patrick Frankham, PhD, MBA, as the Company’s new Chief Executive Officer, effective August 19, 2019.
Dr. Frankham brings more than 25 years of diverse natural products and pharmaceutical experience across both business and research leadership roles in domestic and international markets. A talented product innovator, he is recognized for driving business results by building products through infrastructure, innovation and talent.
Prior to joining Mondias, Dr. Frankham was Chief Executive Officer and a Director of Pivot Pharmaceuticals Inc. since 2014. During the course of his career, he has also founded several healthcare start-ups, including healthcare information technology, services and pharmaceutical companies. His strong scientific background comes from his professional experience with public and private companies, including multinational corporations. He has developed pharmaceutical products in several therapeutic areas and interacted with global regulatory authorities. Notable organizations where he held increasing leadership roles include Boehringer-Ingelheim GmbH, AeternaZentaris, BioAxone Biosciences and ICON Clinical Research. Dr. Frankham obtained his PhD in molecular endocrinology from the Université Laval in Canada, and holds an MBA in finance from the University of Liverpool, in the United Kingdom.
“I would like to welcome Dr. Frankham as Mondias’ new CEO on behalf of the Board of Directors,” said Mr. André Rancourt, Executive Chairman of Mondias. “We are proud to have attracted such a high-profile candidate and believe that Dr. Frankham has the track record to take Mondias to the next stage in its growth plan: a vast expertise in developing and marketing biopharmaceutical and natural health products, strong knowledge of the drug regulatory process, a solid network in both the scientific and the financial community and broad public company experience. We will also ensure that he has the tools and resources he needs to make Mondias a success.”
“Mr. Gravel, our outgoing Chief Executive Officer, will stay on as a consultant to assist Dr. Frankham during a normal transition period,” added Mr. Rancourt. “I wish to thank Mr. Gravel for his many contributions to Mondias, from taking the Company public to his involvement in preparing Mondias for future growth.”
“I was impressed by Mondias’ solid portfolio of natural health products and its CELEXT07 bio-defense stimulant plant extract, which has already attracted considerable interest from multinational corporations in the biopharma and agricultural sectors,” said Dr. Frankham, CEO of Mondias. “My goal in joining Mondias is to develop the portfolio of innovative products to their full market potential while raising awareness of the Company among our stakeholders and potential investors. In the coming weeks, with the help of the Mondias team, I intend to assess how we can best develop and market our products to generate top return on investment for our shareholders.”
Mondias has granted an aggregate amount of 700,000 stock options of the Company to Dr. Frankham as part of his compensation package. 350,000 stock options will vest immediately with the remaining 350,000 stock options vesting on January 1, 2022. The stock options have an exercise price of $0.13 per share and will expire on August 19, 2029.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the healthcare, bio-agriculture and organic markets. The Company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers, biostimulants and biopesticides for use in the agriculture, horticulture, cannabis and hops markets, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
- Published in Mondias Natural, News Home
Mondias announces the results of its annual meeting
Momentum Public Relations
Press Release: June 11, 2019
Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the results of its annual general and special meeting of shareholders (the “Meeting”), which was held yesterday in Montreal, Quebec. All of the nominees listed in the Company’s management information circular dated May 6, 2019, were re-elected as directors.
“This has been a very good first six months for Mondias as a newly listed public company,” said Jean-Philippe Gravel, President and Chief Executive Officer of Mondias. “Our proprietary CELEXT07 bio-defense stimulant plant extract is attracting increasing interest from large players in the agricultural, horticulture and cannabis industries. Our consumer health products sector is also progressing as expected, as we are preparing to launch a new line of sleeping aids products for the second part of 2019. These initiatives, along with others planned for later in the year, will enable Mondias to generate growth and new opportunities in 2019.”
“The Board is pleased with the results obtained to date and is strongly committed in helping Mondias to pursue its strategic growth plan. Our Board has the market expertise and skill set needed to guide the Company in creating value for our shareholders,” added Mr. André Rancourt, Executive Chairman of Mondias.
A total of 43 shareholders were represented in person or by proxy at the Meeting, holding 42,663,175 shares, or 67.57% of Mondias’ issued and outstanding shares.
Detailed results of the vote for the election of directors are set out below:
Nominee |
Votes |
% |
Votes |
% |
André Rancourt |
42,648,175 |
99.96% |
15,000 |
00.04% |
Frank Palantoni |
42,648,175 |
99.96% |
15,000 |
00.04% |
Bertrand Venne |
42,648,175 |
99.96% |
15,000 |
00.04% |
Michel Timperio |
42,648,175 |
99.96% |
15,000 |
00.04% |
Louis Doyle |
42,648,175 |
99.96% |
15,000 |
00.04% |
All other matters presented for shareholder approval at the Meeting were approved, as follows:
- Appointment of UHY McGovern Hurley LLP, Chartered Accountants, as auditors of the Company for the coming year and authorization of the directors to establish their remuneration;
- Amendment and ratification of the Company’s existing stock option plan; and
- Granting of stock options to purchase up to an aggregate of 3,200,000 common shares under the amended rolling option plan.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health-care, bio-agriculture and organic markets. The Company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Business, Life Sciences, Mondias Natural, News Home, Technology
Mondias announces the results of its annual meeting
Momentum Public Relations
Press Releases: June 11, 2019
Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the results of its annual general and special meeting of shareholders (the “Meeting”), which was held yesterday in Montreal, Quebec. All of the nominees listed in the Company’s management information circular dated May 6, 2019, were re-elected as directors.
“This has been a very good first six months for Mondias as a newly listed public company,” said Jean-Philippe Gravel, President and Chief Executive Officer of Mondias. “Our proprietary CELEXT07 bio-defense stimulant plant extract is attracting increasing interest from large players in the agricultural, horticulture and cannabis industries. Our consumer health products sector is also progressing as expected, as we are preparing to launch a new line of sleeping aids products for the second part of 2019. These initiatives, along with others planned for later in the year, will enable Mondias to generate growth and new opportunities in 2019.”
“The Board is pleased with the results obtained to date and is strongly committed in helping Mondias to pursue its strategic growth plan. Our Board has the market expertise and skill set needed to guide the Company in creating value for our shareholders,” added Mr. André Rancourt, Executive Chairman of Mondias.
A total of 43 shareholders were represented in person or by proxy at the Meeting, holding 42,663,175 shares, or 67.57% of Mondias’ issued and outstanding shares.
Detailed results of the vote for the election of directors are set out below:
Nominee |
Votes |
% |
Votes |
% |
André Rancourt |
42,648,175 |
99.96% |
15,000 |
00.04% |
Frank Palantoni |
42,648,175 |
99.96% |
15,000 |
00.04% |
Bertrand Venne |
42,648,175 |
99.96% |
15,000 |
00.04% |
Michel Timperio |
42,648,175 |
99.96% |
15,000 |
00.04% |
Louis Doyle |
42,648,175 |
99.96% |
15,000 |
00.04% |
All other matters presented for shareholder approval at the Meeting were approved, as follows:
- Appointment of UHY McGovern Hurley LLP, Chartered Accountants, as auditors of the Company for the coming year and authorization of the directors to establish their remuneration;
- Amendment and ratification of the Company’s existing stock option plan; and
- Granting of stock options to purchase up to an aggregate of 3,200,000 common shares under the amended rolling option plan.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health-care, bio-agriculture and organic markets. The Company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include the Company’s inability to obtain sufficient financing to execute its business plan; competition; regulation; anticipated and unanticipated costs and delays; the success of the Company’s research and development strategies; the ability to obtain orphan drug status; the applicability of the discoveries made; the successful and timely completion and uncertainties related to the regulatory approval process; the timing of clinical trials; the timing and outcomes of regulatory or intellectual property decisions; and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this news release, and the Company does not undertake any obligation to publicly update them to reflect new information or subsequent events or otherwise unless required by applicable securities legislation.
SOURCE Mondias Natural Products Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2019/11/c3543.html
Contact:
Mondias Natural Products Inc., Jean-Philippe Gravel, Chief Executive Officer, 514-804-4569, jpgravel@mondias.ca; L. Derek Lindsay, Vice President, Corporate Development, 514-594-2372, dlindsay@mondias.ca
- Published in Mondias Natural, News Home
Mondias CELEXT07 latest test results confirm effective suppression of grey mould on hops
Momentum Public Relations
Press Release: May 16, 2019
Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the results from research on the use of its proprietary CELEXT07 bio-defense stimulant plant extract on hops plants, conducted in collaboration with McGill University.
Global hops production is expected to grow by 3.3% to 122,767 metric tons in 2019 (Source: IHGC – Economic Commission Summary Reports, April 26, 2019). Hops production in the United States alone reached a record high of US$618 million in 2017, up 24% from US$498 million in 2016 (Source: U.S. Department of Agriculture). The global hops market is driven by increasing demand for hops in alcoholic beverages, medicinal drugs and cosmetic formulations. Over the next five years, increased demand for various flavours in beer such as pilsner or lager and the rise in popularity for hop-based craft beer are major factors that will significantly fuel the growth of the global hops market (Source: Persistence Market Research).
The objective of the current series of tests was to measure CELEXT07’s efficacy in suppressing and preventing diseases on hops plants. Hops is a genus belonging to the same taxonomic family as cannabis. Mondias’ latest experiments on cannabis and hops served as proof-of-concept of the efficacy of the Company’s botanicals in plant protection and increasing plant survival by eliciting induced resistance.
Summary of the test results:
- Foliar applications of CELEXT07 bio-defense stimulant extract were very effective in suppressing grey mould (caused by Botrytis cinerea) infections on hops, with decreases of 86% in disease severity and 67% in disease incidence.
- A scheduled dose split over three days for the soil drench application of CELEXT07 also proved effective for the prevention/suppression of grey mould on hops, with decreases of 31% in disease severity and up to 50% in disease incidence.
- Foliar and soil drench application of CELEXT07 did not have any phytotoxic effect on hops.
“These latest results continue to confirm that CELEXT07 is very effective in suppressing and preventing a wide range of fungal and bacterial pathogens, and has applications in more than one large market,” said Jean-Philippe Gravel, Chief Executive Officer of Mondias. “As mentioned in our last release, Mondias has secured the production capacity needed to meet demand from potential clients. CELEXT07 is ready to market and we are presently looking at selling our product through various sales channels and markets, including the agriculture, horticulture, cannabis and hops markets.”
With post-harvest losses of one-third of the food produced worldwide for human consumption (Gastavsson et al., 2011) and annual economic losses of $10 billion to $100 billion worldwide due to grey mould and powdery mildew (L. Hua et al., 2018), the market potential for CELEXT07 is considerable.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health care, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
- Published in Business, Life Sciences, Mondias Natural, News Home, Technology
Mondias strengthens its management structure
Momentum Public Relations
Press Release: May 8, 2019
Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the appointment of Mr. André Rancourt as Executive Chairman, and of Mr. Derek Lindsay as Vice President, Corporate Development, effective immediately. Mr. Rancourt was previously Chairman of the Board.
“The appointment of Mr. Rancourt as Executive Chairman clearly strengthens the structure and depth of our management,” said Jean-Philippe Gravel, Chief Executive Officer of Mondias. “Mr. Rancourt’s wealth of expertise, vast network and involvement in day-to-day strategy and operations will greatly contribute to our expansion efforts.”
“We are also pleased to have Mr. Lindsay join the Mondias team. His proven expertise in raising equity and financing projects, structuring creative strategic partnerships, increasing investor awareness and completing acquisitions will be an asset for Mondias as the Company embarks on its next growth phase,” added Mr. Gravel.
Mr. Lindsay is a seasoned financial executive with extensive international experience in accelerating the growth of emerging companies. Over the course of his career, he has been instrumental in raising significant equity and debt financing, completing acquisitions and closing strategic partnerships. Mr. Lindsay holds an M.B.A. from the Tuck School of Business at Dartmouth College and a B.A. from Middlebury College, U.S.A.
Mr. Lindsay’s responsibilities with Mondias include financing, investor relations and acquisition activities, as well as participating in the identification and assessment of new business opportunities, with the goal of accelerating the Company’s growth.
The Company also announces that the board of directors has approved the granting of 650,000 stock options to directors, officers, consultants and employees under the Company’s stock option plan. The exercise price of the options is $0.235 (the closing price of the shares on May 6, 2019). The options will vest in equal instalments over a three-year period and expire on May 6, 2029. The options and the stock option plan are subject to shareholder approval at Mondias’ annual and special shareholder meeting on June 10, 2019.
Pursuant to this stock option grant, the Company has a total of 3,600,408 stock options outstanding, which represents less than 6% of the Company’s issued and outstanding common shares.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health care, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: mondias.ca
- Published in Life Sciences, Mondias Natural, News Home
Mondias receives positive results from greenhouse production tests conducted on CELEXT07 with leading cannabis producer
Momentum Public Relations
Press Release: March 18, 2019
Canada NewsWire
MONTREAL, March 18, 2019
- Foliar application of CELEXT07 bio-defense stimulant extract alone or in combination with a botanically-derived antimicrobial plant extract results in the prevention and suppression of powdery mildew on cannabis leaves.
- CELEXT07 is a strong alternative to synthetic fungicides for cannabis growers in search of eco-friendly alternatives.
- CELEXT07 extract is ready to market: production capacity secured to meet demand from potential clients.
MONTREAL, March 18, 2019 /CNW/ – Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the results of its greenhouse production tests conducted in collaboration with McGill University and a leading cannabis producer on its proprietary CELEXT07 bio-defense stimulant plant extract.
Mondias has been developing CELEXT07 to help prevent fungal growth on plants through its proven ability to boost plant defense systems. The objective of the tests was to measure the product’s efficacy in reducing and suppressing the most common fungal diseases encountered in cannabis through the application of CELEXT07 alone and in combination with a botanically-derived antimicrobial plant extract grown in greenhouse production systems.
Summary of the test results:
- Preliminary results showed that foliar application of CELEXT07 alone resulted in the prevention of powdery mildew on cannabis leaves.
- Foliar application of CELEXT07 combined with the tested botanically-derived antimicrobial plant extract resulted in the prevention and suppression of powdery mildew on the leaves of three commercial varieties of cannabis. This combination was the most effective in protecting the cannabis variety most susceptible to powdery mildew.
- When applied alone or in combination with the tested botanically-derived antimicrobial plant extract as a foliar spray, CELEXT07 did not produce any phytotoxic effects on cannabis leaves.
- Soil drench application of CELEXT07 helped suppress grey mould on hops, a close relative of cannabis.
“These results validate the effectiveness of CELEXT07’s bio-defense stimulant properties and open up a large potential market for Mondias, especially as the testing was done in collaboration with a leading cannabis producer,” said Jean-Philippe Gravel, Chief Executive Officer of Mondias. “Furthermore, cannabis growers are seeking eco-friendly alternatives to pesticides. The results from these greenhouse production tests will allow us to market CELEXT07 to a growing number of Canadian cannabis producers. The product is ready to market, and we have secured the production capacity we need to meet demand from potential clients.”
With post-harvest losses of one-third of the food produced worldwide for human consumption (Gastavsson et al., 2011) and annual economic losses of $10 billion to $100 billion worldwide due to grey mould and powdery mildew (L. Hua et al., 2018), the market potential for CELEXT07 is considerable.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health care, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of this joint venture, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
SOURCE Mondias Natural Products Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2019/18/c6020.html
Contact:
Mondias Natural Products Inc., Jean-Philippe Gravel, Chief Executive Officer, 514-804-4569, jpgravel@mondias.ca
- Published in Cannabis, Life Sciences, Marijuana, Mondias Natural, News Home
Mondias Completes Characterization of CELEXT07 that Confirms Its Biostimulant and Antifungal Capabilities and Expands Its Global Market Potential
Momentum Public Relations
Press Release: February 12, 2019
Mondias Naturals Inc (“Mondias” or “NHP“), (TSXV: NHP), announces that the research collaboration with McGill University has led to the identification of CELEXT07 signatory metabolite compounds, antibiotic properties and functional roles in plant physiology. This will lead to the development of several commercial products to meet emerging needs in bio-agricultural and organic markets and offer new chemical free solutions for the cultivation and food storage industries.
The chemical classes of compounds identified in the CELEXT07 extract confirms the botanical agent’s properties associated with plant defense against biotic stress by boosting the plant’s resistance as well as a biostimulant effect on growth. The identification of these compounds supports the previous research demonstrating CELEXT07’s biostimulant and antifungal protective and treatment properties.
Mr. Jean-Philippe Gravel, CEO of Mondias Naturals stated, “These results validate Mondias’ strategy to develop natural products for agricultural markets including post-harvest sub-markets. The CELEXT07 botanical extract will make a significant contribution to the bio-agricultural and organic markets and allow growers to offer horticultural products grown with no chemical agents. We are excited by this advancement since CELEXT07 is an eco-friendly alternative to synthetic fungicides.”
Postharvest diseases caused by storage fungi are responsible for the estimated loss of about 20 to 25% of harvested fruits and vegetables, and will certainly affect Canada’s new cannabis industry. Some fungi may produce mycotoxins that can cause toxicity to both animals and humans. Mycotoxin contaminations can occur in the field and greenhouse, before and after harvest, and also during post-harvest activities and storage. Mondias has been developing its CELEXT07 products to help prevent fungal growth on plants through its proven ability to increase plants’ defense system.
As previously reported in its December 5, 2018 news release, CELEXT07, when used as a soil drench agent, significantly reduced lesions caused by fungi on two greenhouse growing plants, tomato and lettuce, and significantly reduced lesions on detached leaves. Mondias has been expanding its research activities to target food and crop storage. Mr. Jean-Philippe Gravel, CEO of Mondias Naturals stated, “These results suggest that CELEXT07 botanical extract may become a low-risk solution to the new Canadian and USA cannabis agricultural industries.”
The market potential for CELEXT07 is considerable considering that these infections result in annual economic losses between $10 billion to $100 billion worldwide (L. Hua et al. 2018) and that about one-third of the food produced worldwide for human consumption is lost after harvest (Gastavsson et al., 2011).
About Mondias Natural Products Inc. Mondias specializes in the commercialization and development of evidence based botanical products for the health care, bio agriculture and organic markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Business, Life Sciences, Mondias Natural, News Home, Technology
Mondias Announces an Amendment to its Stock Option Plan
Momentum Public Relations
Press Release: February 11, 2019
Mondias Natural Products Inc. (TSXV: NHP) (“Mondias” or the “Corporation”), a Corporation that specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets, announces that its Board of Directors has approved an amendment to its stock option plan to become effective upon approval by the shareholders of the Corporation at the Annual General Meeting of shareholders to be held later this year and upon receipt of final approval by the TSX Venture Exchange Inc. A copy of the proposed Stock Option Plan will be available from the Chief Executive Officer of the Corporation upon request and will be attached to the Information Circular to be filed on SEDAR, at www.sedar.com, for the upcoming Annual General Meeting of the shareholders.
The Corporation proposes to replace the fixed 20% stock option plan with a rolling 10% stock option plan. Under the rolling 10% stock option plan, the Corporation may grant options to acquire common shares of the Corporation equal to 10% of the issued and outstanding shares from time to time subject to the terms and conditions prescribed by the TSX Venture Exchange Inc. and applicable securities laws.
Currently outstanding options to purchase common shares of the Company granted prior to the amendment will continue to be exercisable and will be governed by and subject to the terms of the amended plan.
Based on the Company’s current issued and outstanding common share amount of 63,135,805, the amended rolling plan maximum is currently 6,313,581 common shares. Prior to the amendments to the plan, the fixed plan maximum was 400,408 common shares.
On January 22, 2019, the Board of Directors had approved the grant, subject to shareholder and regulatory approval, of incentive stock options under the amended 2019, 10% Rolling Stock Option Plan to the directors and officers of the Corporation for the purchase of a total of 2,550,000 shares in its capital. The options are exercisable before January 22, 2029, at the price of $0.235 per share (the closing price of the shares on January 21, 2019). The stock options vest over a 3-year period, with the first vesting period delayed until all regulatory and shareholder approvals are received.
About Mondias Natural Products Inc. Mondias specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit : mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Mondias Natural Products Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2019/11/c1683.html
Contact:
Jean Philippe Gravel, CEO, Telephone: 514-804-4569, Email : jpgravel@mondias.ca
- Published in Business, Life Sciences, Mondias Natural, News Home
Mondias announces agreement with Wisdom of Nature Brokerage to expand retail sales in Ontario and grants stock options
Momentum Public Relations
Press Release: January 25, 2019
Mondias Natural Products Inc (“Mondias” or “Company“), (TSX VENTURE: NHP) announces the signing of a sales representation agreement with Wisdom of Nature Brokerage, a company specializing in the retail sales of Natural Health Products in Ontario. Mondias through its recently acquired Holizen brand, has been operating successfully in the province of Quebec and is now expanding retail operations to Ontario for the first phase of its Canada wide distribution.
Other news
The Board of Directors of the Company has approved the granting of 2,550,000 stock options to directors, officers, consultants and employees of the Company. The exercise price of the options is $0.235 (the closing price of the shares on January 21, 2019). The options vest over a 3-year period.
The above-mentioned options have been granted pursuant to the Mondias’s Stock Option Plan. Following this stock option grant the Company has a total of 2,950,804 stock options outstanding, which represents less than 5% of the Company’s issued and outstanding common shares.
About Wisdom of Nature Inc.
With more than 25 years of experience in the Natural Health Food Industry, Wisdom of Nature, led by its president and CEO Corine Johnson, specializes in sales development and independent/mass market product listing across the province of Ontario. They represent top brands like Strauss, Joy of the Mountain, Nature’s Aid, Abundance Naturally, Cannanda and Pro Santé.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit : mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Life Sciences, Mondias Natural, News Home, Technology
Mondias Provides Update on Natural Fungicide Product Development & Commercialization
Momentum Public Relations
Press Release: December 05, 2018
CELEXT07 a new botanical agent for grey mold;
Mondias to target small fruit cultivation market
Mondias Natural Products Inc (“Mondias” or “NHP“), (TSXV: NHP), updates the market on results after the completion of a second NSERC ENGAGE funded research project with McGill University on its innovative botanical agent CELEXT07. The studies demonstrated that CELEXT07 when used as a soil drench agent at a single dose or repeated doses significantly reduced Grey Mold (Botrytis cinereal) lesions on two horticultural plants, tomato and lettuce.
Large scale greenhouse trials evaluating the efficacy of CELEXT07 extracts in disease suppression of Grey Mold were performed on two horticultural plants. The infection from Grey Mold on non-detached leaves of soil-drenched plants was significantly reduced. Compared to control treatment, disease index decreased by almost 90%. Other experiments demonstrated the ability of CELEXT07 to significantly reduce Grey Mold lesions on detached leaves (P <0.05). The study also showed that from an economical point of view, a single dose treatment was sufficient.
Grey Mold is a plant pathogen that causes significant devastating diseases on over 500 plant species (including fruits and vegetables). These infections result in annual economic losses between $10 billion to $100 billion worldwide (L. Hua et al. 2018). In addition, about one-third of the food produced worldwide for human consumption is lost after harvest (Gastavsson et al., 2011). Infections by fungus are a major factor of food wastage and Grey Mold is considered one of the most important postharvest decays of fresh fruit and vegetables (Romanazzi et al., 2016).
Mondias’ research will pave the road for the commercialization of a new botanical-based agent for prevention and management of Grey Mold infections in horticultural crops as well as the prevention of lesions on harvested crops. The corporation plans to collaborate with agricultural product firms to develop and commercialize products aimed at reducing food wastage. Being a natural botanical extract, the CELEXT07 agent will readily decompose in the environment and such agents are considered low risk by pesticide regulators due to their natural origin.
Mr. Jean-Philippe Gravel, CEO of Mondias Naturals Inc stated, “For the last 4 years Mondias has been studying the properties of CELEXT07 as well as preparing for its commercialization. We are now targeting partnerships for the commercialization of natural products to bring the CELEXT07 botanical agent to the market in 2019.” According to Allied Market Research, the global fungicide product market had revenues of $11 billion dollars in 2015 and is expected to grow to approximately $17 billion dollars by 2022. Mr. Gravel added, “With its commercialization and partnership strategy, Mondias intends to become a key player in this fungicide market offering a natural solution to the prevention of Grey Mold while helping stimulate plant growth.”
About Grey Mold
Grey Mold (Botrytis cinerea) is a fungus that affects many plant species. It is well known for its infections in wine grapes. In viticulture, it is known as “botrytis bunch rot”. The fungus affects more than 200 plant species and can result in serious economic losses to both field and greenhouse grown crops. The fungus can infect mature or senescent tissues, plants prior to harvest, or seedlings. Horticultural crops include vegetables such as lettuce, broccoli, and beans and small fruit crops such as grape, strawberry, and raspberry.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence based botanical products for the health care and bio agriculture markets. The company is already selling both oral and topical botanical agents to help manage unmet medical needs through Holizen Laboratories, one of its divisions. Mondias is also developing botanical based specialty fertilizers for use on household plants, urban gardens, lawns, golf courses, nurseries or greenhouses in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
- Published in Business, Life Sciences, Mondias Natural, News Home
- 1
- 2